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Cross-subtype neutralizing single domain antibodies against influenza present new
opportunities for immunoprophylaxis and pandemic preparedness. Their simple modular
structure and single open reading frame format are highly amenable to gene therapy-
mediated delivery. We have previously described R1a-B6, an alpaca-derived single
domain antibody (nanobody), that is capable of potent cross-subtype neutralization
in vitro of H1N1, H5N1, H2N2, and H9N2 influenza viruses, through binding to a
highly conserved epitope in the influenza hemagglutinin stem region. To evaluate the
potential of R1a-B6 for immunoprophylaxis, we have reformatted it as an Fc fusion
for adeno-associated viral (AAV) vector delivery. Our findings demonstrate that a
single intramuscular injection in mice of AAV encoding R1a-B6 fused to Fc fragments
of different isotypes equipped either, with or without antibody dependent cellular
cytotoxicity (ADCC) activity, was able to drive sustained high-level expression (0.5–
1.1 mg/mL) in sera with no evidence of reduction for up to 6 months. R1a-B6-Fc fusions
of both isotypes gave complete protection against lethal challenge with both pandemic
A/California/07/2009 (H1N1)pdm09 and avian influenza A/Vietnam/1194/2004 (H5N1).
This data suggests that R1a-B6 is capable of cross-subtype protection and ADCC
was not essential for R1a-B6 efficacy. Our findings demonstrate AAV delivery of
cross-subtype neutralizing nanobodies may be an effective strategy to prevent
influenza infection and provide long-term protection independent of a host induced
immune response.
Keywords: influenza, vaccine, adeno associated viral vectors, immunoprophylaxis, immunotherapy, nanobody,
monoclonal antibody, antibody dependent cellular cytotoxicity
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INTRODUCTION
Influenza virus continues to be a major public health concern,
causing both annual epidemics and occasional pandemics (1). In
a pandemic, a new influenza virus emerges and infects the human
population which has little or no pre-existing immunity (2, 3).
Vaccines remain the main method of infection control, however
their timely implementation and poor immunogenicity in certain
vulnerable patient groups remain a considerable problem (4).
Although antiviral drugs such as Oseltamivir are available to
control the spread of the virus their effectiveness is limited in
treating patients with influenza (5, 6). There is clearly an urgent
need for additional approaches and antibodies present new
opportunities for both therapeutic and prophylactic intervention.
Passive transfer of serum antibodies from convalescent patients
has been used in the past (7, 8), however, this approach is of
limited use in a global pandemic emergency. A much more
promising strategy is to use recombinant monoclonal antibodies
(mAbs) against influenza and several are currently in clinical
development (9–13). These rare mAbs bind to functionally
conserved epitopes such as those in the hemagglutinin (HA)
stem, thereby providing strain independent protection. However,
for passive immunotherapy to provide sufficient long-term
protection, frequent repeated injections are required which
would be prohibitively expensive in low resource areas. A more
practical and cost-effective strategy would be to use antibody gene
therapy which would provide long term sustainable protection
through antibody production within the patient.
Viruses have been exploited as gene delivery vectors for many
years owing to their highly evolved mechanisms for efficient
delivery of genetic material to host cells (14). Recombinant
Adeno-Associated virus (rAAV) vectors have been modified
to improve safety and are suitable vectors for clinical gene
therapy (15). The ability of rAAV vectors to provide long term
stable transgene expression in different animal cells, their low
immunogenicity, and overall versatility, make them the vector of
choice for in vivo gene therapy (16–19). AAV-mediated delivery
of broadly neutralizing human monoclonal antibodies against
the HA stem has already been shown as a viable approach to
protect from influenza (20, 21). The intramuscular injection of
AAV8 expressing the cross-subtype neutralizing human mAb
F10 could protect young, old, and immunocompromised mice
from influenza challenge through sustained expression in the
systemic circulation for at least 11 months at levels between
150 and 200 µg/mL (20). Similar studies have investigated the
AAV-mediated delivery of another broadly neutralizing human
mAb, FI6, which was shown to protect mice and ferrets from
lethal influenza challenge. In this study FI6 was delivered
intranasally which may be beneficial as this is the natural site
of influenza infection (22, 23). Despite these findings, significant
challenges remain for the successful development of vectored
immunoprophylaxis for influenza. Although AAV is an excellent
vector for gene therapy, it is still hampered by limitations to
the size and complexity of antibody transgenes that it can
express (20). This is a challenge for antibody gene therapy
given that mAbs are large complex glycoproteins comprising
four separate chains. As such, smaller, simpler binding molecules
expressed from a single open reading frame would be a significant
advantage (19, 21).
Structural analysis of several of the earliest human mAbs
against the influenza HA stem revealed the unusual feature that
they employ only their heavy chains for antigen recognition (10,
13). This implies that the light chains were not required for
binding to these difficult to access epitopes. In addition, some
of the most potent cross-neutralizing human mAbs described
have very low levels of somatic hypermutation and are often
constrained to particular germline genes (10, 11, 13, 24, 25).
This suggests that they may be products of an immediate
and sub-optimal immune response to influenza (26, 27). This
prompted our interest in naturally occurring “heavy-chain only”
antibodies from camelids and our isolation of high affinity
broadly neutralizing single domain antibodies (nanobodies)
against influenza A and B (28, 29). This antibody format is unique
to camelid species (30) and can be isolated from immunized
alpacas as highly optimized single domain binding units that
have gone through extensive somatic hypermutation possibly due
to the alpaca’s limited immune history of exposure to influenza
(31). Nanobodies have several well-described advantages over
conventional mAbs which make them ideal for applications in
infectious disease (32–34). One interesting feature is that they
have a preference for binding to clefts and grooves through
unusually long CDR loops (35). In addition, their simple modular
structure and single gene format enables easy engineering for
different delivery and therapeutic applications (14, 28, 36–38).
This next generation of antibodies has reached a significant
milestone with the approval in September 2018 of the first
nanobody, CaplicizumabTM, for the treatment of a blood clotting
disorder (39).
We have previously described R1a-B6 as a potent alpaca
derived nanobody capable of cross subtype neutralization of
pandemic A(H1N1)2009, highly pathogenic avian influenza
H5N1, H2N2 and H9N2 (28, 40). R1a-B6 neutralizes influenza
through binding to a highly conserved epitope in the HA
stem and blocking the low pH induced conformational change
required for viral membrane fusion. Within this study we have
evaluated if R1a-B6’s potent in vitro neutralizing activity can
translate into in vivo efficacy. As a single domain antibody
fragment of approximately 15 kDa, R1a-B6 would be rapidly
cleared from circulation in a matter of minutes, which would
prohibit any activity in vivo (41, 42). To achieve maximum
protective levels in systemic circulation, additional strategies to
enhance its pharmacokinetics are required, (43) such as fusion
to an antibody Fc domain. The Fc domain is largely responsible
for the extended serum persistence of mAbs by pH dependent
interaction with FcRn and recycling through the kidneys (44). In
addition, the Fc domain mediates interactions with the effector
arm of the immune system and recent reports have suggested
antibody dependent cellular cytotoxicity (ADCC) is required
for efficacy of human mAbs specific for the influenza HA stem
(45, 46).
Recent studies by Laursen and colleagues have also described
cross-neutralizing single domain antibodies to influenza and
furthermore shown in vivo efficacy by intranasal AAV delivery at
the natural site of infection (47). In addition, they describe linking
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multiple single domain antibodies together specific to different
epitopes on HA to provide almost complete protection against
both influenza A and B virus in mouse challenge models. Our
study confirms single domain antibodies can be delivered by gene
therapy but is distinct in that we explore AAV8 intramuscular
rather than AAV9 intranasal delivery of R1a-B6 in different
formats to evaluate the relative importance of the Fc domain
for prophylactic efficacy (47). Direct intramuscular injection
of AAV8 allows for a simple method for crossing the blood
vessel barrier to achieve gene transfer into muscle cells (48,
49). Muscle then becomes a biological factory for expressing
antibodies in vivo and has previously been shown to be effective
in mice against HIV (50) and influenza (20). AAV8 and AAV9
share the same tropism, however, low levels of protein expression
and genome copy numbers of AAV9 has been detected in the
brain and testes, which is an important safety issue for clinical
development of this serotype (51). Our choice of muscle specific
delivery and AAV8 as vector serotype is expected to provide
higher level, more sustainable transgene expression over a longer
period of time than AAV9 mediated intranasal delivery which has
previously been shown to decrease in macaques after 3-4 months
(22, 52, 53).
We report the relative prophylactic efficacy of R1a-B6
delivered in different formats designed to investigate the
importance of the Fc domain for half-life extension and effector
function. Our findings are discussed in the context of designing
the optimum transgene for AAV vector delivery of R1a-B6 to
accomplish long term, safe, broad protection from pandemic




Nanobodies R1a-B6 (28) and a control anti-lysozyme specific
nanobody cAb1 (54) sequences were reformatted as Fc fusions
separated by a mouse hinge region. The mouse CH1 domain was
removed and the C-terminal end of the nanobody was directly
fused to the N-terminus of the mouse hinge region followed by
the CH2-CH3 domains of either mouse IgG2a or mouse IgG1.
All constructs were synthesized (IDT technologies) and cloned
into pcDNA 3.4-TOPO (Invitrogen A14697) for mammalian
expression. Large-scale preparation of endotoxin-free plasmid
DNA using NucleoBond Xtra Midi EF Kit (Macherey Nagel
740420.10) was carried out. We then used the ExpiCHO
Expression System (Thermo Fisher Scientific A21933) to produce
soluble nanobody-Fc fusion proteins. Cell supernatants were
purified using HiTrap Protein A HP (GE Healthcare 17040203)
chromatography. Eluted fractions with high A280 readings that
appeared as bands in the SDS-PAGE gels were pooled and
dialyzed in a 10 L solution of 1X PBS overnight at 4◦C.
In vitro ADCC Reporter Assay
White opaque 96-well Nunclon (Thermo Scientific 165306)
plates were coated overnight at 4◦C with 5 µg/mL
A/California/07/2009(H1N1) NYMC X-179A (NIBSC 09/174).
Sample dilutions of nanobody-Fc ranging from 10 µg/mL to
0.25 ng/mL were made and ADCC Reporter Bioassay was then
carried out as per manufacturer’s instructions (Promega M1201)
and read using the GloMax Navigator (Promega).
Specificity of Nanobody-Fc via ELISA
The nanobody-Fc constructs were tested against influenza
antigen standards from the National Institute for Biological
Standards and Control (NIBSC) as listed in Supplementary
Table 3. Plates were coated overnight with 50 µL/well of 5 µg/mL
influenza virus antigen standard diluted in PBS at 4◦C. Serial two-
fold dilutions ranging from 4 µg/mL to 1 ng/mL of purified R1a-
B6-mIgG1, R1a-B6-mIgG2a, R1a-B6, and cAb1-mIgG2a were
then added. Secondary antibody, anti-mouse IgG (Fc Specific)-
Peroxidase (Sigma A0168) at a 1:2000 dilution was used to detect
nanobody-Fc; while monoclonal anti-polyHistidine-Peroxidase
clone HIS-1 (Sigma A7058) at a 1:1000 dilution was used to detect
R1a-B6. TMB substrate (Thermo Scientific 34029) was added to
the plate and the reaction was stopped with 0.5 M HCl or 0.5 M
H2SO4. Plates were read on a SpectraMax M5 ELISA plate reader
using SoftMax Pro software. Absorbance at 450 nm was taken.
Pseudotype Neutralization Assay
The following pseudotypes with luciferase reporters (55),
A/Korea/426/68(H2N2) (KR/68), A/Vietnam/1194/2004(H5N1)
(VN/04), and A/Hong Kong/1073/99(H9N2) (HK/99) were used.
Serial two-fold dilutions of nanobody-Fc were made ranging
from 32 nM to 1 pM. Influenza pseudotypes at a concentration
of 1.0 × 106 RLU/well were then added to the nanobody-Fc
dilutions and 1.0 × 104 293T cells were added to each well.
Plates were incubated for 48 h at 37◦C and 5% CO2. Supernatant
was then harvested, and plates were read using the GloMax




AAV-R1a-B6-mIgG1, AAV-R1a-B6-mIgG2a, AAV-R1a-B6, and
AAV-cAb1-mIgG2a, were generated by cloning the nanobody
constructs into the AAV2 ITR-containing plasmid pTRUF11.
The rAAV plasmids were transformed in XL-1 Blue (Stratagene
200249) competent cells via heat shock and scaled up in
suspension cultures for large-scale DNA extraction using the
NucleoBond Xtra Midi Endotoxin Free Kit (Macherey Nagel
740420.10). To check for ITR integrity, plasmid DNA was
digested with SmaI (Promega) and run on a 1% (w/v) agarose gel.
rAAV Production
HEK293T cells were grown to a density of 4.0× 107 293T cells in
a final volume of 100 mL per triple flask of Dulbecco’s Modified
Essential Medium (DMEM) (Sigma D6546) supplemented with
10% (v/v) Fetal Calf Serum (FCS) (Sigma 14A138), 1% (v/v)
L-glutamine (Sigma G7513), 1% (v/v) Penicillin-Streptomycin
(PenStrep) (Sigma P0781). Twelve triple flasks (TF) were used
per rAAV construct to make a cell factory. Recombinant AAV
vectors pseudotyped with serotype eight capsid containing AAV2
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ITRs (AAV2/8) were generated by transient transfection using
polyethyleneimine (PEI) (PolySciences 24765-1) of pHelper,
pAAV construct, and pAAV2/8/Rep-Cap. Flasks were incubated
at 37◦C and 5% CO2. After 72 h, virus was harvested
and extracted from the supernatant via ammonium sulfate
(NH4)2SO4 (Sigma A4418) precipitation. Cells in the triple
flask were trypsinized and combined with the supernatant and
subjected to three freeze/thaw cycles and treated with 10,000
U Benzonase (Novagen 70746-4). Tubes were then centrifuged
to clarify the lysate and run on an iodixanol (OptiPrep Sigma
D1556) gradient (51). Virus was then concentrated using
VivaSpin20 (Sartorius VS20S1) and filter-sterilized (0.45 µ m).
rAAV Characterization
Adeno-associated viral capsid particles were quantified using
a discontinuous Laemmli SDS-PAGE setup using standards of
Bovine Serum Albumin (BSA) (Pierce Biotechnology/Thermo
Scientific 23209) as shown in Kohlbrenner et al. (56). Viral
genome size and integrity was determined using alkaline
gel electrophoresis (57). Vector genomes were quantified by
qPCR. rAAV genome sequences corresponding to a 129 bp
fragment (58), of the Cytomegalovirus (CMV) promoter from the
transgene and a 62 bp portion of the Inverted Terminal Repeats
(ITRs) (59) of the AAV vector were amplified.
Tissue Culture Infectious Dose (TCID50)
Determination and Influenza
Microneutralization (MN) Assay
Viral diluent consisting of 500 mL DMEM (Sigma D6546), 1%
(v/v) Pen-Strep (Sigma P0781), 1% Amphotericin B (v/v) (Sigma
A2942), and 1% (v/v) L-glutamine (Sigma G7513) was prepared.
For TCID50 determination, a 10−4 dilution of influenza virus
was made and diluted ten-fold across the plate. Virus dilutions
were transferred to Madin-Darby canine kidney (MDCK) cells
at about 70-90% confluency. Plates were incubated for 1 h at
room temperature. Dilutions were then discarded and replaced
with 100 µL of freshly-prepared Infection Medium [10% (v/v)
10X Minimum Essential Medium (MEM) (Sigma M0275), 0.7%
(v/v) Bovine Serum Albumin fraction V solution 7.5% (Sigma
10735078001), 2% (w/v) NaHCO3 (Sigma S8761), 1% (v/v)
HEPES (Sigma H0887), 0.5% (w/v) DEAE dextran (Sigma 93556),
1% (v/v) Pen-Strep (Sigma P0781), 1% (v/v) L-glutamine (Sigma
G7513), 1% (v/v) Amphotericine B (Sigma A2942), 0.7% (v/v)
Tosyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin
(Sigma T4376)]. Plates were incubated for 72 h at 37◦C and
5% CO2. Supernatants were then transferred to round-bottom
96-well plates and 50 µL of 0.7% (v/v) turkey red blood cells (t-
RBCs) in PBS were added and the highest dilution with complete
hemagglutination in 10 wells in a single row was recorded. The
number of hemagglutination positive wells after this row was
also recorded and TCID50 was calculated using the Reed-Muench
method (60).
For the MN assay, 100 µL of either nanobody-Fc (serially
diluted two-fold from 256 nM to 128 pM) or heat-inactivated
sera from mice treated with AAV encoding transgenes (diluted
1:25 to 1:3200) was added to 100 µL of 103 TCID50/mL
A/California/07/2009/(H1N1)pdm09. A positive control of
ferret antiserum against A/California/07/2009/(H1N1)pdm09
was included. The assay was carried out and neutralization titer
was obtained using HA readout; the MN titre was defined as the
last well showing complete inhibition of hemagglutination.
AAV-Nanobody-Fc Tolerability Study
Twenty-eight female BALB/c mice, 6–8 weeks old, were obtained
from Charles River Laboratories. Mice were divided into four
groups of six for each of the AAV constructs. For every group,
the following AAV concentrations in vector genomes (vg) of
the rAAV-nanobody Fc: (i) 1.0 × 1010, (ii) 3.3 × 1010, and (iii)
1.0 × 1011 were prepared. Each dose (in 50 µL volume) was
given to 2 mice via intramuscular (IM) injection. A control group
consisting of 4 mice was given 50 µL PBS. Mice were bled at 0, 2,
4, 6, 8, 10, 12, 16, 20, and 24 weeks post-AAV injection. At the end
of 24 weeks, all mice were culled, and terminal bleeds collected.
In vivo Challenge Studies in Mice
Forty female BALB/c 6-8-week-old mice were obtained from
Charles River Laboratories. Mice were divided into five groups
of eight. On Day 0, mice from groups 1-4 were injected
intramuscularly (IM) with a 50 µL volume of 1 × 1011 vg
AAV-R1a-B6-mIgG1, AAV-R1a-B6-mIgG2a, AAV-R1a-B6, and
AAV-cAb1-mIgG2a respectively. Mice from group five were
given 50 µL PBS. Thirty-nine (39) days later, mice were bled
to determine serum antibody titers. Six weeks (6) after the
start of the study, mice were challenged intranasally (IN)
with 21 MLD50 A/California/07/2009 (H1N1)pdm09 or 10
MLD50 A/Vietnam/1194/2004 (H5N1) NIBRG-14ma. Weights
and clinical observations were made twice daily for 14 days or
until the endpoint of loss of 20% of initial body weight was
observed, when lungs were harvested, and terminal bleeds were
collected. For the H5N1 challenge experiment, an additional
3 mice per group, were added and culled 3-days post-
challenge, to quantify residual influenza in the lungs and for
histological analysis.
Hemagglutination Inhibition Assay (HAI)
All sera were treated with Receptor Destroying Enzyme (RDE)
(Seiken) in a 1:4 dilution and incubated overnight at 37◦C.
Twenty-five microliters of mouse sera was aliquoted into
duplicate wells and serially diluted two-fold in PBS before
the addition of 4 HAU A/California/07/2009 (H1N1)pdm09 or
A/Vietnam/1194/2004 (H5N1) NIBRG-14ma. After 90 minutes
incubation at room temperature, 50 µL 0.5% (v/v) T-RBCs was
added to each well and HAI titer was determined via the HA
readout as described above for the TCID50 assay.
Histology
Mouse lungs were washed in PBS and fixed with 4%
paraformaldehyde (PFA). Four-micron-thick sections were then
cut using the Leica RM2125 RTS Microtome. Slides were
prepared and stained with hematoxylin and eosin (H&E) (Vector
Laboratories Inc. H-3502). High definition scans were taken
using Pannoramic Digital Slide Scanner (3D HISTECH) and
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analyzed using CaseViewer 2.3 (3D HISTECH). Inflammation
was scored in blinded fashion as follows: 0 = no to minimal
inflammation, 1 = occasional infiltration in bronchioles,
2 = infiltration of bronchioles and slight thickening of
perivascular walls; 3 = mass infiltration of bronchioles, thickening
of perivascular walls, and lung rupture.
Statistical Analysis
All analyses were performed with GraphPad Prism 8.12 for
Windows (GraphPad Software). The Student’s t test was used to
determine differences between two groups.
RESULTS
R1a-B6-Fc Fusions Have Broad
Cross-Subtype Specificity and
Neutralizing Activity Against Influenza
Virus
The cross-neutralizing nanobody R1a-B6 has been shown
previously to bind to a highly conserved epitope in the HA
stem (40) (Figure 1A), which overlaps the fusion peptide and
is predicted to function through inhibiting membrane fusion.
To test the prophylactic potential of R1a-B6 (Figure 1A) and
the requirement for half-life extension or effector functions
we designed four single gene encoding proteins (Figure 1B)
by fusion to a mouse Fc fragment of either an IgG1 or
IgG2a isotype. Mouse IgG isotypes differentially interact with
FcγR on effector cells, with IgG2a being the most potent
having high affinity for activating FcγR, whereas IgG1 is the
least potent preferentially interacting with inhibitor FcγR
(61). After purification, a product of approximately 75 kDa
was seen under non-reducing conditions demonstrating
the formation of a dimeric Fc fusion protein (Figure 1C).
We then tested the ability of R1a-B6-Fc to mediate ADCC
via activation of mouse FcγRIV as detected by a luciferase
reporter assay; and as expected, only R1a-B6-mIgG2a
showed any ADCC activity (Figure 1D). Purified R1a-B6-
Fc fusion proteins were then shown to bind to a broad
panel of whole influenza virus reference reagents (Figure 1E
and Supplementary Figure 1) and neutralize key Group I
Influenza A subtypes, A(H1N1), A(H2N2), A(H5N1), and
A(H9N2) (Supplementary Table 1). As reported previously
(28), converting R1a-B6 into a bivalent format was shown to
increase the breadth of neutralizing activity to include the more
divergent influenza subtype A(H2N2) rather than increasing
maximum levels of potency against A(H1N1) and A(H5N1)
(Supplementary Table 1). We have previously speculated that
this is related to the mechanism of action of R1a-B6 which
mediates its effect after the virus has already attached to the
cell surface and been internalized. We have suggested that
internalization of the virus nanobody complex may be a rate
limiting step in the potency of stem binding antibodies, so
conversion to a bivalent format does not increase potency
above a certain maximum threshold. As such, converting
R1a-B6 from a monovalent to bivalent Fc fusion is seen to
enhance potency for more divergent subtypes [i.e., A(H2N2)
and A(H9N2)] with a lower affinity interaction, whereas
for higher affinity interactions A(H1N1) and A(H5N1),
no further enhancement is seen as a maximum level has
already been reached.
In vivo Expression of Nanobodies by
Intramuscular (IM) AAV Delivery
Upon confirmation of the breadth of reactivity in vitro of
reformatted R1a-B6, we inserted the corresponding transgenes
for R1a-B6-mIgG1, R1a-B6-mIgG2a, R1a-B6, and cAb1-mIgG2a
into a recombinant AAV2/8 vector. Transgenes were packaged
into AAV using triple transfection (57) and characterized by
measuring the number of capsid particles, physical genomes,
and gene products via qPCR (data not shown). Capsid and
viral genome were found to be intact and of high purity. We
then used our AAV viruses for a dose ranging study in mice as
described below.
To test the ability of AAV-mediated delivery to induce muscle
specific expression of R1a-B6 transgenes and to determine the
optimum AAV dose, a dose ranging study of a single IM
injection of 1.0 × 1011 vg (vector genomes), 3.3 × 1010 vg
and 1.0 × 1010 vg of each AAV vector was given to BALB/c
mice. We tested expression levels in mouse sera for a duration
of 24 weeks while observing for any symptoms of stress or
discomfort. Detectable levels of nanobody-Fc fusion were seen
for all vector doses in mouse sera within 2 weeks of injection
(Figure 2A). Nanobody-Fc levels increased, reaching a plateau
during weeks 6–12, with concentrations being maintained at a
stable level for the duration of the 24-week study with no evidence
of reduction. Peak concentrations of ∼560 µg/mL for R1a-B6-
mIgG1,∼1100 µg/mL for R1a-B6-mIgG2a, and∼600 µg/mL for
cAb1-mIgG2a, were detected (Figure 2A). Monovalent R1a-B6
showed very low levels in serum compared to the Fc fusions,
reaching a peak concentration of around 0.36 µg/mL by week
6 which remained for the duration of the study. In all cases,
mice did not show any symptoms of distress or ill health
that could be attributed to AAV or transgene expression for
the full 24 weeks.
In vitro Neutralization of
A/California/07/2009(H1N1) (CA/09) and
Other Strains by Sera From Mice
Receiving AAV Transgenes
To determine if mice that received AAV were expressing
functional R1a-B6, we performed in vitro neutralization
assays against pandemic A/California/07/2009(H1N1)
(CA/09). Terminal sera (24 weeks) from mice expressing
the control nanobody against lysozyme, cAb1, did not
show any neutralization of CA/09, as expected (data not
shown). Similarly, no neutralization of CA/09 was seen with
monovalent R1a-B6, which correlated with serum levels
being approximately 1000-fold lower in molar equivalence
than the levels attained by the Fc fusions (data not shown).
In contrast, sera from mice that received AAV expressing
R1a-B6-mIgG1 and R1a-B6-mIgG2a were able to neutralize
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FIGURE 1 | R1a-B6 reformatted for in vivo gene delivery. (A) Surface structure model of hemagglutinin (HA) trimer of A(H1N1)pdm09 (PDB structure 3AL4) showing
the key epitope residues of R1a-B6, Gly20, Trp21, and Ile45 (shown in red) located in the HA stem region (cyan) (40). The receptor binding site (magenta), fusion
peptide (orange), and head domain (green) are also illustrated. (B) Four constructs, (i) R1a-B6 mouse Fc IgG1, (ii) R1a-B6 mouse Fc IgG2a, (iii) monovalent R1a-B6,
and (iv) negative control mouse Fc IgG2a fusion carrying a nanobody, cAb1 [adapted from Arbabi Ghahroudi et al. (54)], specific for chicken egg white lysozyme were
produced in vitro. These constructs were cloned into an AAV expression system for protein expression in vivo. (C) Expression and purification of nanobody-Fc
fusions. Detection of proteins was carried out under reducing and non-reducing conditions in SDS-PAGE gels. Theoretical molecular weights (MW) for
R1a-B6-mIgG1, R1a-B6-mIgG2a, and cAb1-mIgG2a are ∼37 kDa under denaturing (reducing) conditions, and ∼75 kDA under non-reducing conditions. (D) In vitro
ADCC activation. Activation of luciferase reporter gene is shown in relative luminescence units (RLU) as a function of nanobody-Fc concentration. Each well was
measured in triplicate. (E) Binding of R1a-B6 against a broad range of influenza A subtypes as tested by ELISA. Half maximal effective concentration (EC50) was
measured in duplicate. There was no binding on A/TX/12(H3N2) or B/Brisbane/08 (data not shown). All values above the dotted line indicate no binding activity.
CA/09 (Figure 2B). The level of neutralization directly
correlated with serum concentration as detected by ELISA
which in turn correlated with AAV vector genome dosage
(Figure 2B). The AAV vector dose of 1.0 × 1011 vg gave the
highest nanobody serum titer (Figure 2A) and was chosen for
protection studies.
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FIGURE 2 | AAV dose ranging study of anti-influenza neutralizing nanobody R1a-B6 in mice. (A) Different R1a-B6 constructs and the control nanobody, cAb1, were
given via AAV in vector genome (vg) doses of 1.0 × 1010 vg (green series), 3.3 × 1010 vg (blue series), and 1.0 × 1011 vg (red series). Mice that were given PBS are
indicated by the black series. Nanobodies in serum of BALB/c mice were measured from week 0 to 24. A mouse given 1.0 × 1010 vg of R1a-B6-mIgG2a was culled
before the end of the study due to reasons exclusive of AAV delivery. Each individual series corresponds to a single mouse. The dotted line represents the point
(2 weeks) at which nanobody expression levels were first detected. (B) Neutralizing activity of sera taken from mice 24 weeks after they were injected with different
doses of AAV encoding R1a-B6-mIgG1 and R1a-B6-mIgG2a was measured against 103 TCID50/mL of CA/09. The serum neutralizing titer is expressed as the
reciprocal of the highest dilution at which influenza infection is completely blocked. Mice given R1a-B6 (all doses) did not show any neutralizing activity (data not
shown). For all plots, each point represents an individual mouse serum sample, n = 2 mice/group.
We then determined if AAV mediated expression of R1a-B6
present in mouse sera would react with other influenza strains
belonging to key influenza subtypes. We obtained mouse sera
6-weeks post AAV IM administration of 1.0 × 1011 vg of each
R1a-B6 transgene (n = 8/group) and tested their cross-subtype
specificity and neutralization activity. These mice were naïve
and had not been exposed to influenza so immunoreactivity
to heterologous strains can be attributed solely to R1a-B6
expressed from the AAV transgene in vivo and not to naturally
produced antibodies. Sera from mice expressing R1a-B6-mIgG1
(Figure 3A) and R1a-B6-mIgG2a (Figure 3B) were specific
against all Group I Influenza A subtypes tested. Mice expressing
monovalent R1a-B6 showed lower reactivity against the panel
of whole influenza virus antigen standards (Figure 3C), which
was consistent with its very low serum levels compared to
mice receiving the R1a-B6-Fc fusions. Mice expressing cAb1-
mIgG2a and those given PBS did not show any reactivity
against influenza virus (data not shown). In addition to cross-
subtype specificity, R1a-B6-Fc in mouse sera also demonstrated
potent cross-neutralizing ability against Group I Influenza
A pseudotypes of subtypes H2, H5, and H9 (Figure 3D).
These results demonstrate that R1a-B6-Fc has retained its
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FIGURE 3 | Evaluation of heterosubtypic R1a-B6 reactivity in mouse sera 39 days after IM injection of 1.0 × 1011 vg AAV encoding nanobodies. (A–C) Binding of
R1a-B6 against different influenza subtypes was tested via ELISA. Plates were coated with 5 µg/mL influenza reference reagent (Supplementary Table 3) and the
Absorbance at 450 nm was plotted against a serial dilution of recombinant nanobody for standard curve analysis. Recombinant nanobody concentration in serum
corresponding to the sample binding activity was plotted. Samples were measured in duplicate. All values below the solid line represent no detectable binding
activity. A/Texas/50/2012(H3N2) (TX/12) and B/Brisbane/60/2008 (B/BR/08) served as negative controls. (D) In vitro neutralization against different influenza
pseudotypes was determined via a luciferase-reporter assay and given as IC50 values (IC50 is half maximal inhibitory concentration). All values above the dotted line
indicate no neutralization. For all plots, n = 8 mice/group.
in vitro cross-subtype specificity and neutralizing activity when
produced in vivo.
Protection of Mice From Lethal
A(H1N1)pdm09 (CA/09) Challenge by
AAV-Mediated Delivery of R1a-B6
To determine whether AAV delivery of R1a-B6 transgenes
protects mice from lethal influenza infection, we injected 1× 1011
vg AAV encoding R1a-B6-mIgG1, R1a-B6-mIgG2a, R1a-B6, and
control cAb1-mIgG2a intramuscularly into different groups of
BALB/c mice (n = 8/group). We also included a negative control
group that was given PBS. Thirty-nine days post-AAV injection,
we tested for transgene expression prior to lethal challenge
with influenza. Mice given R1a-B6-mIgG1, R1a-B6-mIgG2a, and
cAb1-mIgG2a have significantly higher concentration in serum
than mice given vectors encoding R1a-B6 or PBS (p < 0.05)
(Figure 4A). In groups receiving nanobody Fc fusions, we
detected 300–500 µg/mL levels of nanobody (Figure 4A),
whereas for the R1a-B6 transgene without Fc, we were unable to
detect any substantial levels in the sera tested.
After confirmation of transgene expression in mouse sera,
we proceeded with influenza challenge via intranasal delivery
of 21 MLD50 (mouse lethal dose) CA/09 42 days after AAV
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FIGURE 4 | Prophylactic efficacy of AAV expressed nanobodies in a mouse challenge model of pandemic H1N1 CA/09. (A) Total nanobody-Fc in serum was
measured by ELISA in samples taken 39 days after IM injection of AAV vectors pre-challenge with CA/09. Comparisons are shown in brackets (*p < 0.05). BALB/c
mice were then infected intranasally with 21 MLD50 (mouse lethal dose) of A/California/07/2009(H1N1)pdm09 42 days post-AAV IM injection. Survival (B) and weight
loss (C) were monitored for 14 days. (D) Naturally induced immune response in mice pre- and post-CA/09 challenge was assessed via Hemagglutination Inhibition
(HAI) titers 39 days post-AAV administration and 3 days pre-challenge (•), and from post-challenge terminals bleeds (◦). HAI titers are expressed as the highest
dilution of serum that inhibited hemagglutination completely. Points below the solid line represent no HAI activity. For panels (A–D), each point represents an
individual mouse. Mean and standard error of eight recipient mice per treatment is shown in panels (A) and (C,D). (E) Binding and activation of mouse FcγRIV
effector cells in mice given nanobody-Fc fusions delivered by AAV. Terminal mouse sera were tested for ADCC activity via activation of mFcγRIV from representative
mice after IM injection of 1.0 × 1011 vg AAV-R1a-B6-mIgG1, AAV-R1a-B6-mIgG2a, AAV-R1a-B6, and AAV-cAb1-mIgG2a. Mice were culled 14 days post-challenge
for R1a-B6-mIgG1, R1a-B6-mIgG2a, and R1a-B6, and 6 days post-challenge for cAb1-mIgG2a. Activity is shown in relative luminescence units (RLU) against
dilution of mouse sera containing nanobody Fc fusions expressed in vivo. Each point is shown as the mean and standard error of three replicates. (F) Representative
histological lung sections from mice that received AAV encoding R1a-B6-mIgG1, R1a-B6-mIgG2a, R1a-B6, cAb1-mIgG2a, and PBS (untreated) post-infection with
CA/09. Lungs were harvested from mice as they exited the study at the days indicated and stained with Hematoxylin and Eosin (H&E). Arrows represent thickening
of the alveolar walls. *Represents Mouse 3 (Supplementary Figure 2 and Supplementary Table 2), the only mouse that survived the CA/09 challenge from the
R1a-B6 group. Scale bar = 100 µm.
administration. Weight loss and clinical symptoms of influenza
were observed for the 14-day study window or until mice
exited the study. Animals expressing the control anti-lysozyme
specific nanobody cAb1-mIgG2a and those given PBS showed
symptoms of influenza including difficulty in breathing, pinched
waists and sunken abdomen 3 days post-challenge. These mice
lost 20% of weight and were culled by day 6 of the study
(Figures 4B,C and Supplementary Figure 2). In contrast, there
was no weight loss or symptoms of influenza infection observed
in mice given R1a-B6-mIgG1 and R1a-B6-mIgG2a (n = 16) for
the duration of the study demonstrating complete protection
from influenza (Figures 4B,C and Supplementary Figure 2).
Mice given monovalent R1a-B6 without mouse Fc, showed
symptoms of influenza infection 6 days post-challenge, which
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FIGURE 5 | Prophylactic efficacy of AAV expressed nanobodies in a mouse challenge model of VN/04 (H5N1) NIBRG-14ma. (A) Total nanobody-Fc in serum was
measured by ELISA in samples taken 39 days after IM injection of AAV vectors pre-challenge with VN/04(H5N1). Comparisons are shown in brackets (*p < 0.05).
Mice were then infected intranasally with 10 MLD50 (mouse lethal dose) of A/Vietnam/1194/2004 (H5N1) NIBRG-14ma 42 days post-AAV IM injection. Survival (B)
and weight loss (C) were monitored for 13 days. (D) Residual viral load was determined as indicated by TCID50/g of tissue from lung homogenates 3 days
post-challenge with 10 MLD50 VN/04. Each dot represents an individual mouse. Comparisons are shown in brackets (p < 0.05). (E) Representative histological lung
sections from mice that received AAV encoding R1a-B6-mIgG1, R1a-B6-mIgG2a, R1a-B6, cAb1-mIgG2a, and PBS (untreated) 3 days post-infection with VN/04
NIBRG-14ma. Lungs were harvested from mice and stained with Hematoxylin and Eosin (H&E). Arrows represent thickening of the alveolar walls and lung ruptures
are represented by dashed lines. Scale bar = 100 µm.
was a delay of 3 days compared to control groups given cAb1-
mIgG2a and PBS (Figure 4C). Seven mice (n = 7) from the
monovalent R1a-B6 group eventually succumbed to infection
and were culled on days 7–8 due to rapid weight loss. However,
a single mouse (Mouse 3) from this group started gaining
weight around day 9 and survived until the end of the study
(Figures 4B,C, Supplementary Figure 2, and Supplementary
Table 2). It was also noted that this mouse was of a higher than
average starting weight.
To compare anti-influenza immune response pre- and post-
CA/09 challenge we used a hemagglutination inhibition (HAI)
assay on terminal mouse serum samples (Figure 4D). HAI is a
surrogate test for the presence of neutralizing antibodies which
bind to the HA head domain and block the receptor binding
site. As expected, pre-challenge samples did not show any HAI
activity as the only anti-influenza antibody present was R1a-B6
which has previously been shown to be negative for HAI (28,
40), as is also the case for other HA stem-binding antibodies.
Post-H1N1 challenge, mice that received AAV encoding cAb1-
mIgG2a and PBS, culled on days 4-6, showed similar HAI
titers as groups given AAV encoding R1a-B6, R1a-B6-mIgG1,
and R1a-B6-mIgG2a, the latter two groups being mice that
survived the influenza challenge with no observable symptoms
of infection. We concluded that after influenza challenge, both
infection-induced anti-head HA antibodies and anti-stem R1a-
B6 nanobodies were present in mouse sera (Figure 4D). These
results suggest that naïve mice are still able to mount a
natural immune response against CA/09 challenge even after
administration of AAV encoding transgenes.
Surprisingly, we did not see any observable difference in
the prophylactic efficacy of mice receiving R1a-B6-mIgG2a
compared to R1a-B6-mIgG1. This suggested ADCC was not
an essential component of the protective mechanism of action
of R1a-B6 in this context notwithstanding that the mouse
IgG2a isotype version of R1a-B6 was capable of mediating
ADCC (Figure 4E).
We also compared the level of inflammation in terminal lung
tissue. At the end of the study (14 days post-challenge), mice
expressing R1a-B6-mIgG1 and R1a-B6-mIgG2a (n = 16) showed
clear bronchioles and air sacs with no signs of inflammation
(Figure 4F). In contrast, mice expressing cAb1-mIgG2a, 6 mice
given R1a-B6, and those given PBS (n = 22) demonstrated
infiltration of the bronchioles and air sacs with thickening of the
perivascular wall (Figure 4F). Two mice from the group given
R1a-B6 (Mouse 3 and Mouse 8) did not show any signs of lung
inflammation (Figure 4F and Supplementary Table 2). Slight
lung infiltration can be seen in lung tissue of mice culled on day 7
given R1a-B6 (Figure 4F).
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Protection of Mice From Lethal A(H5N1)
Challenge by AAV-Mediated Delivery of
R1a-B6
To assess if the prophylactic efficacy of R1a-B6 can extend to
a different influenza subtype, we tested in an H5N1 influenza
challenge model. The study design was the same as that of
the CA/09 challenge except that mice received 10 MLD50 of
NIBRG-14ma (VN/04), a mouse-adapted strain of a re-assortant
virus derived from A/Vietnam/1194/04 (H5N1). Symptoms of
influenza and rapid weight loss were observed 2-days post-
challenge in mice given AAV encoding cAb1-mIgG2a, PBS and
monovalent R1a-B6, which was earlier than those observed after
the CA/09 challenge experiment (Figure 5C and Supplementary
Figure 3). All mice from these groups (n = 24) were culled
by day 4 (Figure 5B). Similar to the CA/09 challenge, all mice
given R1a-B6-mIgG1 and R1a-B6-mIgG2a (n = 16) did not
show any symptoms of influenza or any appreciable weight loss
for the 13 days of the study (Figure 5C), demonstrating the
cross-subtype prophylactic efficacy of the R1a-B6-Fc fusions.
We were also unable to see any difference between the two
different isotype variants of R1a-B6 as both provided complete
protection. However, unlike the CA/09 challenge, we did not see
any delay in the onset of infection in the group that received
R1a-B6 (Figure 5B) suggesting that the level of R1a-B6 sustained
in mouse sera (Figure 5A) was not sufficient to protect mice
against this strain.
To further characterize the extent of protection against
NIBRG-14ma (VN/04) we culled 3 mice per group 3-days post-
challenge in addition to the 8 mice per group as they reached
the mandated study endpoint to evaluate residual virus in the
lungs. Mice given R1a-B6-mIgG1 and R1a-B6-mIgG2a have
significantly lower TCID50/g of VN/04 than mice given R1a-B6,
cAb1-mIgG2a and PBS (∗p < 0.05) (Figure 5D). Specifically,
no virus was detected in the lungs of mice receiving R1a-B6-Fc
fusions 3 days post-challenge whereas virus could be detected in
groups given R1a-B6, cAb1-mIgG2a, and PBS (Figure 5D). The
mice (n = 9) had average viral titers of 106.8 TCID50/g of NIBRG-
14ma (Figure 5D). In contrast to the CA/09 challenge study, we
did not see any HAI activity against H5N1 either pre- or post-
challenge in any of the groups (data not shown). We speculate
that the absence of head specific antibodies, which would be a
surrogate indication of a natural immune response to influenza, is
due to mice needing to be culled earlier, 3–4 days post-infection,
which is insufficient time for mice to mount an immune response.
For mice receiving the R1a-B6-Fc fusions, we speculate that the
virus was cleared before any immune response could be elicited,
which is supported by the complete absence of detectable virus
3 days post challenge (Figure 5D).
We also scored the level of inflammation in lung tissue via
histological staining from the three mice we culled per group
3 days post-challenge. At 3-days post-challenge, lungs taken from
mice expressing R1a-B6-mIgG1 and R1a-B6-mIgG2a (n = 6)
showed no signs of inflammation with clear bronchioles and
air sacs which is consistent with them having no viral load
(Figure 5E), indicating full protection from influenza infection.
In contrast, mice expressing R1a-B6, cAb1-mIgG2a, and those
given PBS (n = 9) demonstrated extensive infiltration of the
bronchioles and air sacs, thickening of the perivascular wall, and
lung ruptures as seen in the accumulation of red blood cells
(RBCs) in the alveolar space (Figure 5E).
DISCUSSION
Vaccination is the mainstay of influenza infection control,
however, high-risk patient groups such as the elderly and
immune-compromised, do not respond well to vaccines (2,
5, 62). As such, there is a need for additional prophylactic
and therapeutic approaches that are independent of the
patient’s immune system and the prior availability of the
matching influenza strain (63, 64). One approach, which is of
considerable interest, is passive immunotherapy or prophylaxis
with broadly neutralizing monoclonal antibodies which bind
to conserved epitopes on influenza HA (10, 13, 20, 65–
67). We have previously described R1a-B6 which has an
epitope overlapping the fusion peptide, suggesting a post-viral
attachment mechanism of action through the inhibition of
viral membrane fusion (28). In this study, we have evaluated
the prophylactic efficacy of R1a-B6 using intramuscular AAV
delivery. We have chosen to explore intramuscular delivery
instead of intranasal delivery as others have chosen (22, 23,
68) as this has been reported to produce higher and more
durable expression levels in systemic circulation (20, 50). For
example in macaques, AAV expression in the nasal cavity was
shown to decrease after 3–4 months which was likely due
to the turnover of nasal epithelial cells and loss of transgene
expression (22). In contrast, the low turnover rate of muscle
cells should, in principle, mean that the AAV transgenes can be
maintained for much longer (52, 53). This delivery method is
also simpler to implement in resource poor settings alongside
other immunizations.
We have expressed R1a-B6 both as a single domain and
as an Fc fusion of IgG1 and IgG2a isotypes to evaluate
the importance of half-life extension and effector function
for in vivo efficacy. We have shown that a single IM
injection gave robust expression of R1a-B6-Fc fusions (0.5–
1.1 mg/mL) in the systemic circulation which was sustained
for a minimum of 6 months with no observable ill effects
(Figure 2A). We did not see any evidence of reduction
over time which suggests that there was no significant
loss of transgenes, transfected cells or immune mediated
clearance of R1a-B6 or AAV vector. The level of production
is higher than previously reported for conventional human
mAbs delivered intramuscularly (50-200 µg/mL) (20) or
intranasally (1 µg/mL) (22, 23). In one case, much lower
expression levels were reported for intranasal delivery of
0.5 µg/mL in nose, 2 µg/mL in lung, and 120 ng/mL
in circulation which decline over time (22). The very high
serum concentration we see in our study might reflect the
simpler nanobody transgene as compared to a conventional
monoclonal antibody which requires the stable assembly of
two light chains and two heavy chains inside the cell for
successful secretion. It will be interesting to directly compare
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the impact of route of vector delivery on antibody efficacy
as at present, it is unclear if localized AAV gene delivery
in the nasal passages will be able to provide long term
durable expression.
We have shown complete protection of mice by R1a-B6-
Fc fusion in challenge models covering two different influenza
subtypes of pandemic potential. The mice that survived had
no residual virus in their lungs and normal lung morphology
with complete viral clearance. We were also able to see an
HAI response post challenge with A(H1N1)pdm09, suggesting
that AAV delivery and expression of R1a-B6 which neutralizes
virus by post attachment mechanisms and is itself HAI
negative did not interfere with the natural immune response
to virus. Surprisingly, monovalent R1a-B6, which was only
detectable at very low levels in circulation (Figure 4A), was
able to delay the onset of infection by at least 3 days after
a lethal challenge with H1N1 (Figure 4C), with one mouse
surviving until the end of the study. We can infer that
continuous AAV production of R1a-B6 partially offsets the rate of
clearance by glomerular filtration in the kidneys, providing some
protection even in the absence of Fc mediated half-life extension.
However, fusion of R1a-B6 to an Fc fragment dramatically
improved its pharmacokinetic and pharmacodynamic properties
allowing protective levels to be reached over an extended
period. The mechanism is expected to be due to FcRn-
mediated recycling or Fc-mediated distribution and retention in
tissues (44).
Monoclonal antibodies which bind to the HA stem have
been described as utilizing additional mechanisms to neutralize
influenza virus in vivo through recruitment of the effector arm
of the immune system via Fc-Fcγ receptor interaction (45, 46).
For instance, HA stem-binding antibodies have been reported
to neutralize influenza virus by binding HA on virally infected
cells and recruiting NK cells to mediate ADCC (69, 70). As
R1a-B6 is functionally equivalent to other HA stem binding
human mAbs (10, 13), it may also have the potential to utilize
these additional mechanisms of action. To evaluate the extent
ADCC might contribute to the in vivo efficacy of R1a-B6 we
re-formatted it as either a mouse IgG2a-Fc fusion (ADCC+)
or a mouse IgG1-Fc fusion (ADCC-) to ensure compatibility
with mouse FcγRs as confirmed in vitro (Figure 1D). As
protection was complete with R1a-B6 formatted with either
isotype we were not able to see any obvious difference in
efficacy between R1a-B6-Fc fusions in vitro (Figure 1E and
Supplementary Table 1) or in vivo (Figures 4B, 5B). This
contrasts with previous studies using passive transfer of the stem
binding human mAb F16 which was similarly tested as a mouse
IgG1 and IgG2a in the context of the mouse FcγR system. In
this study, only mice that received F16-mouse-IgG2a showed
100% survival from lethal PR8 (H1N1) challenge whereas mice
that received F16-mouse-IgG1 did not survive (46). However,
further studies by the same group showed that the requirement
for FcγR interactions and ADCC was dose dependent with
the inference being that efficacy through passive transfer of
high doses of FI6 was FcγR interaction independent (45). We
speculate, as we have been able to generate very high stable
concentrations in serum using intramuscular AAV delivery of
R1a-B6-mIgG2a and R1a-B6-mIgG1, that viral neutralization
via inhibiting viral membrane fusion is sufficient to provide
protection with no need for FcγR interactions. In addition, the
observation of a protective effect of monovalent R1a-B6, albeit
limited, is an unexpected finding and again suggests continual
expression in vivo may to some extent offset the need for Fc
effector functions.
This independence from the host immune system is an
attractive facet to include when considering the optimal antibody
format for long-term expression in vivo against a variable
pathogen. Eliminating the need for an Fc mitigates some of
the concerns of antibody dependent enhancement of influenza
(71–73) mediated by interactions with the effector arm of the
immune system or pro-inflammatory functions that can lead to
cytokine release and other toxic side effects (74). In addition,
this may reduce the risk of transgene immunogenicity through
Fc mediated uptake and antigen presentation by immune cells
(70, 75). The hypothesis that the effector arm of the immune
system is not essential for R1a-B6 to provide sufficient protection
against influenza opens up new opportunities for designing an
optimized transgene using alternative approaches to half-life
extension (76).
In this study we have shown that the use of AAV vectors
to deliver R1a-B6 through a single IM injection is an attractive
approach to confer broad-based protection against important
influenza subtypes (77) which can enhance preparedness against
future potential influenza pandemics. In addition, our data
suggest that the potency of R1a-B6 does not depend on the
coupling of Fc effector functions to HA binding for neutralization
of influenza. Highly pathogenic avian influenza H5N1, as well
as viruses of subtype H2N2 and H1N1 continue to represent
pandemic threats and while pre-pandemic vaccines against
these strains have been stockpiled by some governments, there
is uncertainty as to exactly what strain could emerge or
if these vaccines would be sufficiently antigenically matched
to be effective particularly in at risk patient groups. Our
alternative approach mitigates these risks and combines the
advantages of AAV mediated gene therapy with highly potent
cross-neutralizing nanobodies against influenza to provide
broad protection independent of the prior availability of the
influenza strain and the need for a natural host induced
immune response.
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